29 articles for MT Lai
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
Merck Research Laboratories
Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic pain.
Merck Research Laboratories
SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition.
Merck Research Laboratories
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
Johnson & Johnson Pharmaceutical Research & Development
Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses.
Merck Research Laboratory
Synthesis and progesterone receptor binding affinity of substituted 1-phenyl-7-benzyl-4,5,6,7-tetrahydro-1H-indazoles
TBA
Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1.
Merck Research Laboratories
Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta-amyloid.
TBA
Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors.
Merck Research Laboratories
Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness.
Johnson & Johnson Pharmaceutical Research & Development
Rational design and synthesis of selective BACE-1 inhibitors.
Merck Research Laboratories
Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase.
Merck
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
Merck Research Labs.
Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif.
Merck Research Laboratory
Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
Merck Research Laboratories
Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants.
Merck Research Laboratory
Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
Merck Research Laboratories
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
Merck Research Laboratories
Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Merck
Synthesis and Antiviral Evaluation of Carbocyclic Nucleoside Analogs of Nucleoside Reverse Transcriptase Translocation Inhibitor MK-8591 (4'-Ethynyl-2-fluoro-2'-deoxyadenosine).
Idenix An Msd
N2-(2-methoxyphenyl)pyrimidine derivative, method for preparing same, and pharmaceutical composition for cancer prevention or treatment containing same as active ingredient
Korea Research Institute of Chemical Technology
Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.
Glaxosmithkline